ClinicaliQ Trial Snapshot
- A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes) — Recruiting • Phase III • Cardiology / Cardiovascular • NCT07241390.
- What is being tested: Orforglipron (LY3502970), a GLP-1 receptor agonist, is being evaluated for its effects on cardiovascular outcomes compared to placebo over approximately 5 years in a phase III outcomes trial.
- Patient eligibility overview: Adults with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD) are eligible; this encompasses patients with established coronary, cerebrovascular, or peripheral artery disease, and/or those with moderate-to-advanced renal impairment.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to measure cardiovascular outcomes with orforglipron compared with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Participation in the study will last about 5 years.
Eligibility Snapshot
- : * Have established ASCVD and/or CKD
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.